Nauka w multiQure

W multiQure regularnie publikujemy i prezentujemy nasze osiągnięcia naukowe w czasopismach naukowych, monografiach czy podczas konferencji i sympozjów na całym świecie.

Wiemy, że to jest doskonały test dla naszych pomysłów i świetna ewaluacja naszych wyników przez środowisko naukowe i ekspertów z różnych dziedzin. To także sposób na ciągły rozwój na najwyższym poziomie i według najlepszych standardów naukowego świata.

RNAi · Publikacje
RNAi · Patenty
Immunoonkologia · Publikacje
Immunoonkologia · Postery

RNAi

CAG-targeting artificial miRNA with reduced off-target risk for efficient lowering of pathogenic polyglutamine proteins
1 kwietnia
2026

CAG-targeting artificial miRNA with reduced off-target risk for efficient lowering of pathogenic polyglutamine proteins

NAR Molecular Medicine Vol. 3 April 2026
Link
A CAG repeat-targeting artificial miRNA lowers the mutant huntingtin level in the YAC128 model of Huntington's disease
1 czerwca
2022

A CAG repeat-targeting artificial miRNA lowers the mutant huntingtin level in the YAC128 model of Huntington's disease

Molecular Therapy: Nucleic Acids Vol. 28 June 2022
Link
Universal RNAi Triggers for the Specific Inhibition of Mutant Huntingtin, Atrophin-1, Ataxin-3, and Ataxin-7 Expression
1 marca
2020

Universal RNAi Triggers for the Specific Inhibition of Mutant Huntingtin, Atrophin-1, Ataxin-3, and Ataxin-7 Expression

Molecular Therapy: Nucleic Acids Vol. 19 March 2020
Link

Patenty

Nucleic acid molecule and use of the nucleic acid molecule in therapy of diseases induced by expansion of trinucleotide CAG repeats
31 października
2024

Nucleic acid molecule and use of the nucleic acid molecule in therapy of diseases induced by expansion of trinucleotide CAG repeats

Olejniczak M., Kotowska-Zimmer A., Pewinska M., Lewicki P., Siemionow K.
United States Patent Application US 2024/0360443 A1
Link
Nucleic acid molecule and use of the nucleic acid molecule in therapy of diseases induced by expansion of trinucleotide CAG repeats
16 października
2024

Nucleic acid molecule and use of the nucleic acid molecule in therapy of diseases induced by expansion of trinucleotide CAG repeats

Olejniczak M., Kotowska-Zimmer A., Pewinska M., Lewicki P., Siemionow K.
European Patent Application EP 4 446 415 A1
Link
Nucleic acid molecule, expression cassette, expression vector, eukaryotic host cell, induction method of RNA interference in eukaryotic host and use of the nucleic acid molecule in therapy of diseases induced by expansion of trinucleotide CAG repeats
25 czerwca
2019

Nucleic acid molecule, expression cassette, expression vector, eukaryotic host cell, induction method of RNA interference in eukaryotic host and use of the nucleic acid molecule in therapy of diseases induced by expansion of trinucleotide CAG repeats

Krzyzosiak W., Olejniczak M., Galka-Marciniak P., Fiszer A.
United States Patent US 10,329,566 B2
Link
Nucleic acid molecule, expression cassette, expression vector, eukaryotic host cell, induction method of RNA interference in eukaryotic host and use of the nucleic acid molecule in therapy of diseases induced by expansion of trinucleotide CAG repeats
15 maja
2018

Nucleic acid molecule, expression cassette, expression vector, eukaryotic host cell, induction method of RNA interference in eukaryotic host and use of the nucleic acid molecule in therapy of diseases induced by expansion of trinucleotide CAG repeats

Krzyzosiak W., Olejniczak M., Galka-Marciniak P., Fiszer A.
United States Patent US 9,970,004 B2
Link

Immunoonkologia

Integrin Alpha v Beta 6 and Its Implications in Cancer Treatment
15 października
2022

Integrin Alpha v Beta 6 and Its Implications in Cancer Treatment

Brzozowska E., Deskmukh S.
"International Journal of Molecular Sciences" (2022)
Link
pH-responsive antibodies for therapeutic applications
22 stycznia
2021

pH-responsive antibodies for therapeutic applications

Klaus T., Deshmukh S.
"Journal of Biomedical Science" (2021)
Link
In Chemico Modification of Nucleotides for Better Recognition
1 października
2018

In Chemico Modification of Nucleotides for Better Recognition

Jurek P., Matusiewicz M., Mazurek M., Jelen F.
Y. Dong (red.) "Aptamers for Analytical Applications" (2018)
Link

Postery

Generation of chemically modified aptamers to capture human C5 complement component in myasthenia gravis treatment
5 kwietnia
2022

Generation of chemically modified aptamers to capture human C5 complement component in myasthenia gravis treatment

Guzdek J., Majewska J., Piskorz M., Velez Pires F., Dobosz P., Carter D., Krzaczek K., Bąkowski T., Sok-Grochowska A.
Aptamers 2022, Oxford, UK
Pobierz
Development of a bispecific antibody for colorectal cancer: Functional activity evaluation via a biophysical cell-based assay and surface plasmon resonance
25 października
2021

Development of a bispecific antibody for colorectal cancer: Functional activity evaluation via a biophysical cell-based assay and surface plasmon resonance

Pires F., Skulski M., Dudek A., Dobosz P., Kołodziejski J., Carter D.
EMBO Practical Course - Biomolecular interaction analysis 2021: From molecules to cells
Pobierz
Chemically-modified aptamers generation to recognize relevant bacterial antigens and antibiotic resistance proteins
15 kwietnia
2021

Chemically-modified aptamers generation to recognize relevant bacterial antigens and antibiotic resistance proteins

Czarnecka M., Puchała M., Guzdek J., Radzińska M., Carter D., Darżynkiewicz ZM., Sołtys K., Adamowicz-Skrzypowska A., Ahmadi Y., Barišić I., Sok-Grochowska A.
Aptamers Virtual 2021, Oxford, UK
Pobierz
Aptamer-enabled adsorber device for specific removal of anti-aquaporin-4 antibodies
3 września
2020

Aptamer-enabled adsorber device for specific removal of anti-aquaporin-4 antibodies

Czarnecka M., Puchała M., Guzdek J., Radzińska M., Dąbrowska B., Sok-Grochowska A., Lopko M., Sołtys K., Darżynkiewicz Z., Liputa E., Carter D., Żurek A., Bąkowski T.
Aptamers Virtual 2020, Oxford, UK
Pobierz
Development Of A Fully Human Antibody Against A Key Immune Checkpoint Modulator
18 listopada
2019

Development Of A Fully Human Antibody Against A Key Immune Checkpoint Modulator

Dudek A., Kasprzyk O., Klaus T., Opalinska M., Swiat M., Kolodziejski J., Blaszczyk R., Dzwigonska M., Sydor P., Kolodziejczyk R., Poznar M., Carter D., Soltys K., Wawrzyniak M., Deshmukh S.
PEGS, Lisbon, Portugal
Pobierz
Discovery Of Antibodies For Immunotherapy Of CRC Using A Proprietary Phage Display Platform
18 listopada
2019

Discovery Of Antibodies For Immunotherapy Of CRC Using A Proprietary Phage Display Platform

Kasprzyk O., Klaus T., Witkowicz A., Wilgan B., Swiderski L., Zurek A., Dudek A., Berezowski M., Kostyn A., Blazejewska A., Orlowski M., Krzaczek K., Sztyler M., Jakimowicz P., Soltys K., Carter D., Wawrzyniak M., Deshmukh S.
PEGS, Lisbon, Portugal
Pobierz
PureSelect2 - a novel phage display platform for in vitro selection of therapeutic antibody fragments
30 kwietnia
2018

PureSelect2 - a novel phage display platform for in vitro selection of therapeutic antibody fragments

Matusiewicz, M., Sok, A., Margas, E., Swiat, M., Zurek, A., Wilgan, B.
PEGS, Boston, USA
Pobierz
Modular platform for modified aptamers – a selection case study
11 kwietnia
2018

Modular platform for modified aptamers – a selection case study

Jurek P., Adamowicz A., Sok A., Mazurek M.
Aptamers 2018, Oxford, UK
Pobierz
Modular platform for modified aptamers
28 czerwca
2017

Modular platform for modified aptamers

Jurek P., Adamowicz A., Sok A., Mazurek M.
Aptamers-in-Bordeaux 2017, Bordeaux, France
Pobierz
Phage Display and SELEX brought together – a bivalent aptamer-antibody conjugate for VEGFR specific targeting
31 marca
2015

Phage Display and SELEX brought together – a bivalent aptamer-antibody conjugate for VEGFR specific targeting

Jurek, P., Matusiewicz, M., Piksa, M., P. Mazurek, MP., Jakimowicz, P., Jeleń, F.
Aptamers 2015, Oxford, UK
Pobierz
Menu Zamknij

Używamy plików cookie, aby zapewnić najlepszą jakość przeglądania, analizę ruchu w witrynie i zarządzanie reklamami.

multiQure